Recognizing Tardive Dyskinesia from Reglan Use in Illinois: What You Need to Know

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Education to Targeted Risk Awareness

If you or a loved one has been taking Reglan and noticed uncontrollable facial or limb movements, you may be seeing early signs of tardive dyskinesia. Decades of pharmacovigilance have established that long-term or high-dose metoclopramide use can lead to this serious movement disorder. This page outlines the key symptoms to watch for and the testing and evaluation process in Illinois.

Understanding Reglan and Its FDA-Approved Uses

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan, stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning underscores the importance of using Reglan for the shortest duration necessary and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Tardive Dyskinesia: Symptoms, Mechanism, and Risk Factors

Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities. These movements can be disfiguring and may persist even after the medication is discontinued. The FDA warns that Reglan can also suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the FDA advises avoiding treatment for longer than 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves metoclopramide's action as a dopamine receptor antagonist. By blocking dopamine receptors in the brain, particularly in the basal ganglia, metoclopramide can disrupt normal motor control, leading to the development of TD. This risk is dose-dependent and cumulative, meaning that longer exposure and higher total doses increase the likelihood of developing the disorder. The FDA's boxed warning emphasizes that the risk of TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, Reglan is not recommended for use in pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Legal Considerations for Illinois Patients: Statute of Limitations

From a legal perspective, patients in Illinois who have developed TD after using Reglan may have claims related to inadequate warnings. The FDA's boxed warning clearly states the risks, but questions may arise about whether healthcare providers and patients were adequately informed about the potential for TD, especially with longer-term use. The statute of limitations for product liability claims in Illinois generally requires that a lawsuit be filed within two years from the date the injury was discovered or should have been discovered. For TD, this timeline can be complex because symptoms may develop gradually and may not be immediately recognized as related to Reglan use. The FDA warning advises immediate discontinuation of Reglan if signs or symptoms of TD occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), but patients may not always be aware of this recommendation. Attorney considerations for affected patients include documenting the timeline of Reglan exposure, the onset of TD symptoms, and any medical records that show the duration and dosage of treatment. The FDA's indication for Reglan limits its use to 12 weeks for gastroesophageal reflux and advises against longer-term use for diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was prescribed Reglan for longer than these recommended durations, this could be a factor in a legal claim. Additionally, the FDA warns against concomitant use of other drugs known to cause TD and advises avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to follow these precautions may also be relevant.

Timeline of Exposure and Harm: Key Evidence for Claims

The timeline between exposure and documented harm is critical. TD can develop after months or years of Reglan use, and symptoms may persist or become permanent even after the drug is stopped. The FDA's boxed warning highlights that TD is potentially irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For legal purposes, the date of diagnosis or the date when symptoms became noticeable is often used to determine the start of the statute of limitations. Patients in Illinois should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances, including the duration of Reglan use, the presence of any warning signs, and the timing of their TD diagnosis. In summary, Reglan is associated with a well-documented risk of tardive dyskinesia, as outlined in the FDA's boxed warning. The risk increases with longer treatment duration and higher cumulative doses. Patients in Illinois who have developed TD after using Reglan should be aware of the statute of limitations and seek legal advice to explore their options. The FDA's warnings provide a clear basis for understanding the risks, but individual cases may vary based on the specifics of exposure and harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-related tardive dyskinesia claims in Illinois?

In Illinois, the statute of limitations for product liability claims generally requires that a lawsuit be filed within two years from the date the injury was discovered or should have been discovered. For tardive dyskinesia, this timeline can be complex because symptoms may develop gradually. It is important to consult with an attorney to determine the specific deadline for your case.

How does Reglan cause tardive dyskinesia?

Reglan (metoclopramide) acts as a dopamine receptor antagonist, blocking dopamine receptors in the brain, particularly in the basal ganglia. This disruption of normal motor control can lead to the development of tardive dyskinesia. The risk increases with longer treatment duration and higher cumulative doses, as highlighted in the FDA's boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What should I do if I developed tardive dyskinesia after taking Reglan?

If you developed tardive dyskinesia after taking Reglan, you should immediately discontinue the medication as advised by the FDA (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Document your timeline of Reglan exposure, onset of symptoms, and medical records. Consult with an attorney experienced in pharmaceutical litigation to assess your legal options, especially regarding the statute of limitations in Illinois.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Reglan (metoclopramide)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.